Financial Performance - The company's operating revenue for the first half of the year reached ¥587.48 million, representing a 17.41% increase compared to ¥500.35 million in the same period last year[4]. - The net profit attributable to shareholders was ¥109.44 million, a decrease of 2.29% from ¥112.00 million in the previous year[4]. - The net profit after deducting non-recurring gains and losses was ¥104.97 million, which is a 10.57% increase from ¥94.94 million year-on-year[4]. - The company's cash flow from operating activities was ¥51.76 million, up 18.39% from ¥43.72 million in the same period last year[4]. - The company's total assets increased by 3.28% to ¥4.81 billion from ¥4.66 billion at the end of the previous year[4]. - The gross profit margin for the reporting period was 56.03%, indicating a high level of profitability[99]. - The company reported a significant increase in financial expenses, which rose by 625.93% to CNY 18.11 million from CNY 2.49 million in the previous year[107]. - The company experienced a 35.70% increase in operating costs, which rose to CNY 258.34 million from CNY 190.38 million in the previous year, attributed to changes in product structure[107]. - The company reported a net cash outflow from investment activities of CNY -343.19 million, a 48.64% improvement from CNY -668.21 million in the previous year[107]. Research and Development - The company's R&D investment accounted for 17.60% of operating revenue, down from 18.76% in the previous year[4]. - Research and development (R&D) expenses totaled ¥103,387,808.27, reflecting a 10.16% increase compared to ¥93,848,708.75 in the previous year[31]. - The proportion of total R&D expenses to operating income decreased by 1.16 percentage points to 17.60% from 18.76% year-on-year[31]. - The company is developing complex multi-chiral drugs, including a 21-step synthesis of Posaconazole and a 69-step synthesis of Elotuzumab, indicating a focus on high-difficulty drug development[20]. - The company is advancing its antibody-drug conjugate (ADC) technology, which has seen multiple approvals from the FDA, positioning it as a key area in biopharmaceuticals[26]. - The company is focusing on the development of targeted conjugated drugs, which combine effective drugs with tumor-targeting peptides or antibodies to enhance delivery and reduce side effects[29]. - The company is actively investing in innovative technology firms to enhance its future drug pipeline and maintain competitiveness in the global market[77]. - The company has multiple products in various stages of development, including a 3,000-unit soft capsule for hyperlipidemia and a 1,000-unit API for antifungal treatment, with approvals expected soon[34]. Market Strategy and Expansion - The company plans to enhance its market presence through strategic partnerships and product commercialization efforts[11]. - The company aims to increase its market share in the domestic market through successful bidding in national drug procurement programs[15]. - The company is focusing on international expansion, primarily exporting to the EU, the US, and countries along the Belt and Road[124]. - The company has registered several APIs in major international markets, including the US, Europe, and Japan, enhancing its global market presence[40][47]. - The company is committed to maintaining a flexible business model and expanding its global market presence[68]. Assets and Investments - Cash and cash equivalents at the end of the period amounted to ¥910,191,258.60, representing 18.91% of total assets, a decrease of 22.89% compared to the previous year[128]. - Accounts receivable reached ¥326,160,717.89, accounting for 6.78% of total assets, with a year-on-year increase of 6.35%[128]. - Inventory increased to ¥327,674,948.41, making up 6.81% of total assets, reflecting a growth of 16.88% from the previous year[128]. - Long-term equity investments rose by 48.27% to ¥52,448,745.42, now representing 1.09% of total assets, primarily due to new investments in Suzhou Boxikang Pharmaceutical Technology Co., Ltd.[128]. - Fixed assets increased significantly by 74.19% to ¥700,666,030.24, accounting for 14.55% of total assets, mainly due to the completion of construction projects in Taixing and Shandong[128]. - The company approved an increase in investment for the Taixing Phase II project from ¥310 million to ¥500 million[137]. Environmental and Regulatory Compliance - The company has established various emergency response plans for environmental incidents, which are regularly trained[167]. - There were no administrative penalties due to environmental issues during the reporting period[168]. - The company has committed to environmental monitoring every six months, with increasing investment in environmental protection corresponding to the rise in pollutant emissions[187]. - The company’s subsidiaries BoRui Pharmaceutical and BoRui Taixing are listed as key pollutant discharge units by environmental protection authorities[183]. - The company has not disclosed any major litigation or arbitration matters during the reporting period[197]. - The company has not engaged in any significant related party transactions during the reporting period[198]. Financial Management - The company signed a loan agreement with the International Finance Corporation for USD 50 million, with collateral provided by subsidiaries[117]. - The company has a long-term loan balance of USD 50 million as of June 30, 2023[119]. - Financial expenses increased due to rising interest costs from foreign currency loans, prompting the company to optimize its loan structure[127]. - The company is committed to reducing the scale of foreign currency loans to gradually lower the financial expense ratio[127].

| 保荐机构 | 民生证券股份有限公司 | 上市公司简称 | 博瑞医药 | | --- | --- | --- | --- | | 保荐代表人 | 黄丹青、邵航 | 上市公司代码 | 688166 | 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕1883 号）核准，并经上海证 券交易所同意，博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或 "公司"）向社会公众公开发行人民币普通股（A 股）股票 41,000,000 股，每股 发行价格为人民币 12.71 元，募集资金总额 521,110,000.00 元，扣除承销及保荐 费用、会计师费用、律师费用、信息披露费用及其他发行手续费共计人民币 81,125,361.23 元后，募集资金净额为人民币 439,984,638.77 元。上述募集资金已 于 2019 年 10 月 31 日全部到位，且经公证天业会计师事务所（特殊普通合伙） 审验并出具了苏公 W[2019]B079 号《验资报告》。 民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 2023 年半年度持续督导跟踪报 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2023-062 博瑞生物医药（苏州）股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"、"本公司" 或"公司"）董事会根据中国证券监督管理委员会《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》的 规定，编制了《2023 年半年度募集资金存放与使用情况的专项报告》。 一、募集资金基本情况 （一）2019 年首次公开发行股票募集资金情况 1、实际募集资金金额、资金到账时间 根据中国证券监督管理委员会出具的《关于同意博瑞生物医药（苏州）股份 有限公司首次公开发行股票注册的批复》（证监许可〔2019〕1883 号），公司首 次向社会公众公开发行人民币普通股（A 股）41,000,000 股，每股面值人民币 1 元，每股发行价格为人民币 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2023-060 博瑞生物医药（苏州）股份有限公司 第三届监事会第十九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"或"博瑞医药"） 第三届监事会第十九次会议于 2023 年 8 月 23 日以现场会议加通讯表决方式在 C27 栋会议室召开。本次会议通知以及相关材料已于 2023 年 8 月 13 日以邮件方 式送达公司全体监事。 监事会认为：公司 2023 年半年度报告的编制和审议程序符合法律法规和《公 司章程》的规定。报告内容真实、准确、完整的反映了公司 2023 年上半年经营 的实际情况，未发现参与 2023 年半年度报告编制和审议人员有违反保密规定的 行为。监事会保证公司 2023 年半年度报告及其摘要披露的信息真实、准确、完 整，其中不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、 准确性和完整性承担个别及连带责任。 表决结果：5 票同意；0 票反对；0 ...

会议召开地点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 证券代码：688166 证券简称：博瑞医药 公告编号：2023-059 博瑞生物医药（苏州）股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 28 日（星期一）上午 10:00-11:00 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 21 日（星期一）至 8 月 25 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bright-gene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）将于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况， ...

证券代码：688166 证券简称：博瑞医药 公告编号：2023-037 博瑞生物医药（苏州）股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 15 日(星期一) 下午 13:00-14:30 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 本次投资者说明会以视频录播结合网络文字互动方式召开，公司将针对 2022 年度经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 15 日下午 13:00-14:30 （二）会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频 ...

Corporate Social Responsibility - The company donated a total of 350,400 CNY in cash during the reporting period[4] - The company has implemented a collective contract to protect employee rights and ensure fair compensation practices[5] - The company has received multiple honors for its intellectual property management, including recognition as a national intellectual property advantage enterprise[17] Investor Relations - The company held three earnings briefings during the reporting period to enhance investor communication[13] - The company has set up a dedicated investor relations section on its website to facilitate communication with investors[15] - A total of 105 announcements were disclosed by the company in 2022, ensuring transparency in information disclosure[16] Quality Management - The company has established a supplier management system to ensure quality control and compliance with regulations[9] - The company has established a comprehensive quality management system to monitor and enhance product safety[10] - No product recalls occurred in 2022 due to safety and health reasons, indicating effective product safety management[10] Shareholder Commitments - The company has committed to a share lock-up period of 36 months starting from November 8, 2019, for major shareholders including Yuan Jiandong and Zhong Weifang[1] - The company has received commitments from various investment partnerships to not transfer or manage their shares during the lock-up period, ensuring stability in shareholding[2] - The company has outlined a long-term commitment from major shareholders regarding their shareholding intentions, which is detailed in the IPO prospectus[3] - The company has established measures to avoid any potential competition with its major shareholders, ensuring alignment of interests[4] - The company has committed to repurchase shares if it is found to have engaged in fraudulent issuance during the IPO process[5] - The company has a commitment to maintain the integrity of its operations and avoid conflicts of interest with its major shareholders[6] - The company has outlined specific penalties for shareholders who violate their commitments, ensuring accountability[7] - The company has received commitments from shareholders to not engage in similar business activities that could compete with the company[8] - The company has established a framework for resolving any potential conflicts of interest that may arise in the future[9] - The company has ensured that all commitments made by shareholders are binding and cannot be revoked during their control period[10] - The company has committed to avoiding any business competition with its controlling shareholders, ensuring no similar business activities will be conducted by them or their controlled entities[34] Financial Performance - The company's operating revenue for 2022 was CNY 1,017,331,488.33, a decrease of 3.33% compared to CNY 1,052,408,590.87 in 2021[114] - The net profit attributable to shareholders for 2022 was CNY 239,623,172.71, down 1.77% from CNY 243,951,048.34 in the previous year[114] - The net cash flow from operating activities increased by 76.78% to CNY 311,259,089.32 in 2022, compared to CNY 176,075,346.56 in 2021[114] - The company's total assets grew by 56.97% to CNY 4,661,272,248.84 at the end of 2022, up from CNY 2,969,615,063.74 at the end of 2021[114] - The net assets attributable to shareholders increased by 30.60% to CNY 2,191,643,269.63 at the end of 2022, compared to CNY 1,678,188,732.58 at the end of 2021[114] - Research and development expenses accounted for 20.35% of operating revenue in 2022, an increase of 3.88 percentage points from 16.47% in 2021[116] - The basic earnings per share for 2022 was CNY 0.58, a decrease of 3.33% from CNY 0.60 in 2021[116] - The company reported a total of CNY 25,984,845.17 in non-recurring gains and losses for 2022, compared to CNY 19,633,858.57 in 2021[119] Market Trends - The global biopharmaceutical market is expected to reach $1.711 trillion by 2025, with a CAGR of 5.3% from 2021 to 2025[71] - The Chinese generic drug market was approximately ¥906.9 billion in 2021, showing a year-on-year growth of 7.39%[74] - The oncology treatment market is projected to grow from $193 billion in 2022 to $377 billion by 2027, with a CAGR of 14.3%[75] Research and Development - The company is focusing on developing high-quality generic drugs and innovative drugs to meet unmet clinical needs, particularly in oncology and chronic diseases[81] - The company has established multiple drug technology research platforms, including fermentation semi-synthesis, multi-chirality drug, non-biological macromolecule, drug-device combination, and conjugated drug platforms, covering various therapeutic areas such as antifungal, antiviral, immunosuppressive, and oncology[85] - The company is enhancing its R&D capabilities to align with the industry's shift towards quality and innovation, aiming to capture a larger share of the international market[74] - The company is actively pursuing regulatory approvals in multiple international markets to enhance its global presence[108] - The company is committed to developing antibody-drug conjugates (ADC) as a key area in its oncology research, with several ADC drugs recently approved by the FDA[171] Product Development - The company has developed complex multi-chiral drugs, including Posaconazole with four chiral centers and 21 synthesis steps, and the anticancer drug Elagolix with 19 chiral centers and 69 synthesis steps[109] - The company has received drug registration approval for the injectable formulation of Curbetadine, which is currently in the small trial phase[192] - The company has received drug registration approval for the inhalation solution of Budesonide, which is in the pilot test phase and targets asthma treatment[197] - The company is developing inhalation products, with several formulations in the pilot stage and clinical approval for Atropine Eye Drops already obtained[169] Financial Commitments and Guarantees - The company provided guarantees totaling 50,000,000 RMB, which represents 22.81% of the company's net assets[59] - The company has reported a total of 17,000,000 RMB in related party transactions for 2022, with actual amounts totaling 4,773,900 RMB, indicating a significant variance[54] - The company has completed construction and equipment debugging for the Suzhou high-end injectable drug production project, which complies with cGMP standards[144] Strategic Initiatives - The company is actively investing in innovative biotech firms, including BRIGHT INNOVATIVE LP, focusing on early-stage biomedicine and health technology[148] - The company is focusing on expanding its global market presence and enhancing international operational capabilities as part of its strategic initiatives[126] - The company is expanding its market presence through direct customer development and partnerships with local agents, leveraging its strong reputation for product quality[94]

Financial Performance - The company reported a revenue of CNY 304,937,396.25 for Q1 2023, representing a year-on-year increase of 22.77%[4] - Net profit attributable to shareholders was CNY 70,769,470.45, reflecting a growth of 16.48% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 69,711,194.90, up by 15.58% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.17, an increase of 13.33% from the previous year[4] - In Q1 2023, the company achieved product sales revenue of CNY 267.94 million, a year-on-year increase of 19.90%[37] - The revenue from raw material products was CNY 221.18 million, up 6.50% year-on-year[37] - The revenue from formulation products reached CNY 46.75 million, a significant increase of 196.10% year-on-year, accounting for 17.45% of total product sales revenue, up 10.38 percentage points from the previous year[37] - Technology revenue amounted to CNY 24.64 million, reflecting a growth of 38.35% compared to the same period last year[37] - Equity income reached CNY 12.37 million, representing a substantial increase of 75.69% year-on-year[37] - Operating profit for Q1 2023 was RMB 75,605,620.79, an increase from RMB 65,287,387.64 in Q1 2022[45] Research and Development - Total R&D investment amounted to CNY 48,657,672.09, which is 15.96% of the revenue, a decrease of 1.25 percentage points compared to last year[4] - The company submitted 27 domestic patent applications and 6 international patent applications in Q1 2023, with a total of 397 patent applications filed to date[19] - The company reported a total of 205 valid patents, including 197 invention patents, as of March 31, 2023[19] - The company’s research and development center project is in the equipment installation and debugging phase, with significant advancements in the construction of the production base[21] Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 4,777,033,986.25, a 2.48% increase from the end of the previous year[5] - In Q1 2023, the company achieved a total asset of approximately CNY 4.78 billion, an increase from CNY 4.66 billion in the previous quarter, reflecting a growth of about 2.5%[22] - The company’s total liabilities increased to approximately CNY 1.86 billion from CNY 1.83 billion, indicating a growth of about 1.6%[24] - The total liabilities decreased slightly to CNY 2,408.38 million from CNY 2,419.59 million year-on-year[26] - The total equity increased to CNY 2,368.65 million from CNY 2,241.69 million year-on-year[27] Cash Flow and Investments - The company's net cash flow from operating activities was CNY 25.06 million, compared to a negative cash flow of CNY 29.65 million in the same period last year[32] - The company reported a net increase in cash and cash equivalents of CNY -162.47 million, compared to CNY -8.75 million in the same period last year[35] - Cash and cash equivalents decreased to approximately CNY 1.02 billion from CNY 1.18 billion, representing a decline of about 13.7%[22] - The company’s long-term equity investments decreased slightly to approximately CNY 33.92 million from CNY 35.37 million, a decline of about 4.1%[24] - The company’s short-term borrowings increased to approximately CNY 164.35 million from CNY 124.38 million, reflecting a rise of about 32.2%[24] Infrastructure Development - The company completed 90% of the curtain wall construction for the workshop and 95% for the headquarters building, indicating significant progress in infrastructure development[21] - The company is preparing for trial production at several new facilities, including the Taixing raw material and formulation production base[10] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[44] - The company is not applying new accounting standards for the year 2023[48]

Group 1: Company Development and Strategy - The company focuses on R&D-driven strategies, aiming to develop both high-barrier generic drugs and highly differentiated innovative drugs [2][4] - R&D investments will be aligned with operational cash flow to select suitable business models [2] - The company plans to maintain a balance in R&D investments while controlling them within reasonable limits [2] Group 2: Financial Performance - In Q1 2022, the gross profit margin increased due to significant growth in high-margin products, such as: - Anifin raw materials: Revenue increased by 127.39%, gross margin over 80% [3] - Micafungin raw materials: Revenue increased by 83.33%, gross margin over 70% [3] - Dapoxetine raw materials: Revenue increased by 406.53%, gross margin over 70% [3] - The company's products are entering commercialization, leading to economies of scale and effective cost control, significantly enhancing gross profit levels [3] Group 3: Market Expansion Plans - The company aims to enhance its global market presence, focusing primarily on the European and American markets while also exploring Southeast Asia, Belt and Road Initiative markets, the Middle East, South America, and North Africa [3] - The company has established production bases in Suzhou and Taixing, along with an internationally aligned quality management system [3] Group 4: Product Development Focus - The company emphasizes high-barrier inhalation products, such as dry powder inhalers and soft mist inhalers, which have significant clinical and commercial value [4] - In innovative drug development, the focus will be on: - Antibody-drug conjugates (ADCs) for targeted delivery in cancer treatment, with potential for improvement in penetration and efficacy [4] - Drug-device combinations that leverage a technological platform for sustainable innovation [4]

证券代码：688166 证券简称：博瑞医药 博瑞生物医药（苏州）股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | |---------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| ...